GSK launches $2.5 billion restructuring plan to fund late-stage pipeline and offset upcoming HIV drug patent loss

GSK reported $2.4 billion in impairment charges for the second quarter and unveiled a three‑year restructuring designed to save roughly $2.5 billion.

The company says the savings will be redirected into its late‑stage portfolio and pipeline, helping to sustain investment as the U.S. patent for its HIV medicine dolutegravir expires in 2028.

CEO Luke Miels explained that the plan will simplify the organization and reallocate capital, targeting £1.9 billion (about $2.5 billion) in savings by 2029, with part of the funds used to improve margins and profitability.

The restructure will include global job cuts, though no specific headcount figures were provided. GSK pledged to share more details as the plan progresses.